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Abstract
Background: Active serologic surveillance of H5N1 highly pathogenic avian influenza (HPAI) virus in humans and poultry is
critical to control this disease. However, the need for a robust, sensitive and specific serologic test for the rapid detection of
antibodies to H5N1 viruses has not been met.
Methodology/Principal Findings: Previously, we reported a universal epitope (CNTKCQTP) in H5 hemagglutinin (HA) that is
100% conserved in H5N1 human isolates and 96.9% in avian isolates. Here, we describe a peptide ELISA to detect antibodies
to H5N1 virus by using synthetic peptide that comprises the amino acid sequence of this highly conserved and antigenic
epitope as the capture antigen. The sensitivity and specificity of the peptide ELISA were evaluated using experimental
chicken antisera to H5N1 viruses from divergent clades and other subtype influenza viruses, as well as human serum
samples from patients infected with H5N1 or seasonal influenza viruses. The peptide ELISA results were compared with
hemagglutinin inhibition (HI), and immunofluorescence assay and immunodot blot that utilize recombinant HA1 as the
capture antigen. The peptide ELISA detected antibodies to H5N1 in immunized animals or convalescent human sera
whereas some degree of cross-reactivity was observed in HI, immunofluorescence assay and immunodot blot. Antibodies to
other influenza subtypes tested negative in the peptide-ELISA.
Conclusion/Significance: The peptide-ELISA based on the highly conserved and antigenic H5 epitope (CNTKCQTP) provides
sensitive and highly specific detection of antibodies to H5N1 influenza viruses. This study highlighted the use of synthetic
peptide as a capture antigen in rapid detection of antibodies to H5N1 in human and animal sera that is robust, simple and
cost effective and is particularly beneficial for developing countries and rural areas.
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Introduction
H5N1 highly pathogenic avian influenza (HPAI) virus remains
an important global concern as it has caused devastating outbreaks
in poultry worldwide, and over 500 human cases with a
substantially high fatality rate of 60% [1]. If H5N1 could exhibit
sustained transmissions among humans, an unusually severe
pandemic threat would be inevitable.
An effective surveillance system for H5N1 infection in
animals and humans is of vital importance in the control of
this disease. Currently available serologic tests include hemag-
glutination inhibition (HI), microneutralization assay, enzyme-
linked immunosorbent assay (ELISA) and agar gel precipitation
test. The HI test is considered the ‘‘gold standard’’ for
subtyping. However, low sensitivity and subtype cross-reactivity
significantly limit the value of this assay [2,3]. Although the
microneutralization assay overcomes these limitations and is
currently the recommended test for H5N1 infection, this test is
labour-intensive and requires biocontainment facilities [4]. A
commercial ELISA allows rapid serologic surveillance of H5N1
infection has been reported. However, false positive results were
observed in cross-reacting antibodies of seasonal influenza
viruses [5].
Peptide based enzyme immunoassay (ELISA) has been widely
used for the sero-diagnosis of bacterial and viral infections [6,7]. It
provides the advantage of enhanced specificity and can be easily
implemented into a simple, rapid, sensitive and relatively cheap
diagnostic kit [8,10,11]. Previously, we reported an immunogenic
epitope comprising the sequence ‘‘CNTKCQTP’’ that is highly
conserved in the H5 hemagglutinin (HA) [9]. Antibodies to this
epitope were readily detected in H5N1 immunized animals or
convalescent human sera in the format of epitope-blocking ELISA.
However, this epitope-blocking ELISA requires the presence of a
H5 antigen and relies on the specific monoclonal antibody that
binds to the epitope. As a result, it is relatively expensive and
impractical for development into a rapid diagnostic kit that is
suitable for field use.
In the present study, we developed a novel peptide ELISA for
H5N1 antibody detection by incorporating the peptide comprising
the amino acid sequence ‘‘CNTKCQTPMGAINSS’’. The
specificity of the peptide ELISA was assessed by experimental
chicken antisera against multiple clades of H5N1 viruses, including
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e20737clades 0, 1, 2.1, 2.1.1, 2.1.2, 2.1.3, 2.2, 2.3, 4, 7 and 8, as well as
other subtype influenza A viruses and convalescent human sera.
Furthermore, we demonstrate the superior specificity of the
peptide ELISA in comparison with hemagglutinin inhibition (HI),
dot blot and immunofluorescence assay (IFA) that utilize
recombinant HA1 proteins as diagnostic antigen. In addition, this
method is a simple, highly sensitive and specific for a particular
subtype H5N1. In future this method could be a good
serodiagnosis method for effective replacement of serum neutral-
ization which needs heightened containment and live virus.
Materials and Methods
Viruses
Influenza A viruses isolated in Indonesia were obtained from
Ministry of Health (MOH) (Table 1). Influenza A viruses from
other subtypes were obtained from Agri-food and Veterinary
Authority (AVA) of Singapore (Table 2). Reverse genetics system
has allowed the generation of reassortant viruses containing HA
and NA from different clades of H5N1 and other subtype viruses
in A/Puerto Rico/8/1934 (PR8) genetic background [12]
(Table 1, 2). High and Low pathogenic viruses were propagated
in 11-day old embryonated chicken eggs and virus titers were
determined by hemagglutinin assay [13]. Viruses were clarified by
centrifugation at 130006g for 15 min and inactivated using binary
ethylenimine (BEI) to a final concentration of 0.01 M for 24 h at
37uC [14] and stored at 280uC. All experiments with live viruses
were performed in a biosafety level 3 containment laboratory in
compliance with CDC/NIH and WHO recommendations [15]
and also approved by the Agri-food and Veterinary agency and
Ministry of Health of Singapore.
Reverse Genetics
The HA and NA genes of 10 H5N1 viruses from clade 0, 1, 2.1,
2.1.1, 2.1.2, 2.1.3, 2.2, 2.3, 4, 7 and 8 as well as eight non-H5
subtypes viruses (H1N1, H2N9, H6N8, H8N4, H11N9, H12N5,
H13N6 and H16N3) (Table 1,2) were synthesized by GenScript
based on the sequences from the NCBI influenza database. The
synthesized HA and NA genes were cloned into a dual-promoter
plasmid for influenza A reverse genetics [12]. Reassortant viruses
were rescued by transfecting plasmids containing HA and NA
together with the remaining six gene plasmids derived from A/
Puerto Rico/8/34 (H1N1) into co-culture of 293T and MDCK
cells by using Lipofectamine 2000 (Invitrogen Corp). At 72 h post
transfection, culture medium from the transfected cells was
inoculated into 11-day-old embryonated chicken eggs or MDCK
cells. The HA and NA genes of reasssortant viruses were
sequenced to confirm the presence of introduced HA and NA
genes.
Experimental serum samples
Experiments involved animals were undertaken in a biosafety
level 3 facilities at Temasek Lifesciences Laboratory, Singapore.
Animals were handled according to Institutional Animal Care and
Use Committee (IACUC) regulations. Inactivated H5N1 and
other subtype viruses (Table 1 and 2) were emulsified in ISA-70
(SEPPIC, France) adjuvant and injected intramuscularly to the
groups of three weeks old white leghorn chickens (n=4). The
booster was given twice at two-week intervals. Sera were prepared
from the blood collected 10 days after 1st injection and 2
nd
injection. Antibody responses to the homologous strains were
evaluated by HI as described below.
Human serum samples
Three serum panels from human (n=50) were used. First panel
comprised human sera from 15 individuals with confirmed H5N1
infection collected from the National institute of Hygiene and
Epidemiology, Vietnam and MOH of Indonesia. Three out of 15
samples were collected 2 days after the onset of infection
(collection date of other samples was unknown). Second panel
comprises 15 human sera from patients recovered from seasonal
influenza A virus infections from Singapore General Hospital
(SGH) (no details on the collection date were provided). The third
panel consisted of 20 serum samples from healthy volunteers with
no influenza vaccination or any illness related to influenza,
obtained from Ministry of Health (MOH) of Indonesia (n=20).
Table 1. H5N1 subtype influenza A viruses used in this study.
Strain Subtype Clade Host
A/Hongkong/156/97* H5N1 0 human
A/Honglong/213/03* H5N1 1 human
A/Indonesia/CDC1031/07* H5N1 2.1 human
A/Egypt/0636-NAMRU3/07* H5N1 2.2 human
A/Nigeria/6e/07* H5N1 2.2 human
A/Anhui/1/05* H5N1 2.3 human
A/Vietnam/HN/31242/07* H5N1 2.3 human
A/Indonesia/CDC7/06 H5N1 2.1.1 human
A/Indonesia/CDC523/06 H5N1 2.1.3 human
A/Indonesia/CDC594/06 H5N1 2.1.2 human
A/Indonesia/CDC669/06 H5N1 2.1.3 human
A/goose/Guiyang/337/06* H5N1 4 avian
A/chicken/Shanxi/2/06* H5N1 7 avian
A/chicken/Henan/12/04* H5N1 8 avian
*Reassortant viruses generated from reverse genetics.
doi:10.1371/journal.pone.0020737.t001
Table 2. Influenza A viruses H1–H13 and H16 subtypes used
in this study for specificity evaluation.
Strain Subtype Host
A/Brisbane/59/2007* H1N1 human
A/Singapore/TLL52/2009* H1N1 human
A/duck/Nanchang/4-184/2000* H2N9 avian
A/Chicken/Singapore/02 H3N2 avian
A/Chicken/Singapore/92 H4N1 avian
A/Hongkong/213/03* H5N1 human
A/Shorebird/DE/12/04* H6N8 avian
A/Chicken/Singapore/94 H7N1 avian
A/duck/Yangzhou/02/05* H8N4 avian
A/chicken/Singapore/Sin/98 H9N2 avian
A/mandarin duck/Singapore/Sin/98 H10N5 avian
A/pintail/Alberta/84/2000* H11N9 avian
A/pintail/Alberta/49/03* H12N5 avian
A/gull/Maryland/704/1977* H13N6 avian
A/herring gull/Delaware/712/1988* H16N3 avian
*Reassortant viruses generated from reverse genetics.
doi:10.1371/journal.pone.0020737.t002
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A recombinant baculovirus harboring the HA1-encoding region
(amino acids 1–325) from the A/goose/guangdong/2006 HA
gene was generated as described previously [16,17] Sf-9 cells were
seeded in 96-well plates and infected with H5-HA1 recombinant
baculovirus. At 36 h post-infection, the cells were fixed with 4%
paraformaldehyde for 30 min at room temperature. All the washes
were performed with phosphate buffered saline (PBS). Fixed cells
were incubated with experimental chicken sera in 1:250 dilution at
37uC for 1 h, washed and incubated with a 1:40 dilution of
fluorescein isothiocyanate (FITC)- conjugated goat anti-chicken
IgG (Dako, Denmark). Antibody binding was visualized using
Olympus IX 71 microscope (OLYMPUS, Japan) with appropriate
barrier and excitation filters [18].
Table 3. Cross-HI test with antiserum obtained from immunized chickens.
Antigen Antiserum Titer
a
H1 H2 H3 H4 H5 H6 H7 H8 H9 H10 H11 H12 H13 H16
H1N1
b 1 2 8 -8 --8 ---- - 4 - -
H2N9 - 128 - - 16 - - 8 - - - 4 - -
H3N2 - - 128 4 - - - - 2 -----
H4N1 - - 4 128 - - - - - -----
H5N1 - 8 - - 128 - - - 2 ----2
H6N8 - 4 ---1 2 8 --------
H7N1 - - ----1 2 8 -------
H8N4 - - ---4 -1 2 8 ------
H9N2 - - 2 - - - - - 128 -----
H10N5 - - -------1 2 8 ----
H11N9 - - -------- 1 2 8 - - -
H12N5 8 - -------- - 1 2 8 - -
H13N6 - - ----------1 2 8 -
H16N3 - - - - 4 - - - - ----1 2 8
aThe HI titer of the sera were adjusted to 128 with the homologous vı ´rus (Table 2).
bA/Singapore/TLL52/2009*.
‘‘-’’ NIL.
doi:10.1371/journal.pone.0020737.t003
Figure 1. Immunofluorescence assay using Sf-9 cells infected with baculovirus harbouring HA1 of A/Goose/Guangdong/H5N1. After
36 hrs of infection, the cells were fixed and incubated with experimental chicken H1–H13 and H16 antisera and binding was detected with FITC-
conjugated goat anti-chicken IgG. Strong fluorescence signal was observed with all experimental raised anti-H5 sera (only representative image is
shown). Anti- H1, H2, H3, H6, H7 and H12 showed weak fluorescence signal, indicating some degree of cross reactivity. Antisera of other subtypes did
not bind to the H5 HA1antigen. Control chicken serum (c) was also included as a negative control.
doi:10.1371/journal.pone.0020737.g001
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Viral RNA was isolated with TRIzol (invitrogen,USA) from
allantoic fluid containing H1–H16 subtype viruses (except H14
and H15 due to their rarity). The HA1 genes were amplified and
cloned into pET -28a vector (Novagen, Germany) followed by
transformation into Escherichia coli BL-21 competent cells for HA1
expression. Hexa-histidine tagged fusion HA expression was
induced by the addition of 1 mmol/L IPTG for 4 h and purified
on a Nickel-NTA column (Qiagen, Germany) [19].
Hemagglutinination inhibition assay
Hemagglutination inhibition (HI) assay was performed as
described previously [20]. Briefly, receptor destroying enzyme
(RDE) treated sera were serially diluted (2 fold) in V bottom 96-
well plates. Approximately 8 HA units of viral antigens were
incubated with the sera for 30 min at room temperature, followed
by the addition of 1% chicken red blood cells. The HI titre was
the highest serum dilution in which agglutination was not
observed.
Immunodot blot
Purified proteins H1–H13, and H16 rHA1 proteins (1 mg) were
blotted onto the 0.45 mm nitrocellulose membrane (Bio-rad)
using a 96-well hybridot manifold (BIORAD). The membrane
was then blocked with 5% nonfat milk in PBS containing 0.1%
tween 20 (PBST) at room temperature for 30 min. All the rinsing
was done with PBST for 3 times. The membrane was further
incubated with diluted chicken sera (1:250) in PBST at room
temperature for 1 hr. Following rinsing, the membrane was
incubated with horseradish peroxidase- conjugated goat anti-
chicken IgG (Kirkegaard & Perry Laboratories, Gaithersberg,
Md.) for 1 hr at room temperature. Bound antibodies were
detected by the addition of DAB and H2O2 as the substrate, as
described previously [21].
Microneutralization assay
This assay describes the serum neutralizing antibody titers
[3]. Briefly, MDCK cells were seeded at 1610
6 cells/well in 96-
well culture plates and cultured at 37uCt of o r mam o n o l a y e r .
Serial two fold dilutions of RDE treated sera were mixed
separately with 100 TCID50 of H5N1 strain incubated at room
temperature for 1 h, and added to the monolayer of MDCK
cells in triplicate wells. The neutralizing titers reported are the
highest serum dilution in which no cytopathic effect was
observed.
Epitope-Blocking ELISA
Epitope-blocking ELISA (EB-ELISA) was performed as de-
scribed before [9]. Briefly, U-bottomed 96-well ELISA plates were
coated with purified recombinant HA of A/Indonesia/CDC/
669/06 (500 ng/well) or inactivated concentrated H5N1 virus
(10 mg/well) and incubated overnight at 4uC in coating buffer
(0.1 mol/L carbonate/bicarbonate, pH 9.6). Antigen-coated
plates were washed with PBS containing 0.05% Tween 20,
pH 7.5 (PBST) and non-specific sites were blocked with 100 mL
blocking buffer (PBS containing 5% skim milk) for 40 min at
37uC. Serially diluted (two-fold) test serum samples (100 mL) was
added to each well and incubated for 45 min at 37uC. The wells
were rinsed four times with PBST and incubated with 150 ng of
HRP conjugated anti-H5 monoclonal antibody (mAb) 5F8 in
100 mL PBST for 1 h at 37uC. Following rinsing with PBST,
signal was developed with 100 mL of 3, 3, 5, 5-tetramethyl
benzidine (TMB, Sigma, USA) and the reaction was stopped by
adding 0.1N Sulfuric acid. The optical density (OD) was
Figure 2. Separation of purified recombinant HA1 proteins of H1–H13 and H16 [14] subtypes (38 kDa) in SDS-PAGE.
doi:10.1371/journal.pone.0020737.g002
Figure 3. Recognition of H1–H13 and H16 rHA1 proteins by anti-H5N1 (A/Indonesia/CDC669/06-a representative for H5N1) chicken
sera in immunodot blot. The membrane was blotted with column purified HA1 proteins of different subtypes, followed by incubation with anti-
H5N1 chicken sera (A) or control chicken sera (B), and binding was evaluated with HRP-conjugated anti-chicken IgG.
doi:10.1371/journal.pone.0020737.g003
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samples show .30% inhibition is considered positive.
H5 peptide ELISA
Peptide of amino acid sequence ‘‘CNTQCNTPMGAINSS’’ used
in the ELISA was synthesized by PEPNOME Pte Ltd, China. Flat
bottom96-wellamino immobilizerplates(NUNC,USA)werecoated
with 10 mg/well of peptide in coating buffer (10 mM NaHCO3
buffer, pH 9.6) and incubated at 4uCo v e r n i g h t .P la t e sw e r ew a sh e d3
times with PBST after each incubation. Peptide-coated plates were
blocked by incubation with 200 mL blocking buffer (1% BSA in
PBST) at 37uC for 1 h, and incubated either with 100 mLo fc h i c k e n
antisera or with anti-human serum in blocking buffer at 37uCf o r
45 min. Antibody binding was detected by incubation with 100 mLo f
species specific HRP conjugates (Kirkegaard & Perry Laboratories,
Gaithersberg, Md.) diluted 1:2000 in blocking buffer at 37uCf o r
45 min. The chromogen development was mediated by the addition
of 100 mL freshly prepared substrate solution (3, 39,5 ,5 9-
tetramethylbenzidine, Sigma). The reaction was stopped by addition
of 50 mL of 4 M sulfuric acid and the OD was measured at 450 nm.
Results
Antisera to H1-H13 and H16 subtypes and H5N1 clades
A panel of antisera to influenza A viruses of subtype H1 to H13,
and H16 was raised to determine the specificity of the peptide
ELISA to H5 antibodies (Table 2). Reverse genetics was used to
rescue viruses from H5N1 clades or HA subtypes that were not
available in our laboratory as reassortants harboring internal genes
(PB1, PB2, PA, NP, M and NS) from A/Puerto Rico/8/34. Ten
H5N1 reassortant viruses habouring HA and NA of H5N1 viruses
from clades 0, 1, 2.1, 2.1.1, 2.1.2, 2.1.3, 2.2, 2.3, 4, 7 and 8
(Table 1) and eight additional subtypes H1N1,H2N9, H6N8,
H8N4, H11N9, H12N5, H13N6 and H16N3 (Table 2) were
generated. These viruses were used to raise antisera in chickens to
evaluate the peptide ELISA. The antisera were standardized to HI
titre of 128 using the homologous viruses (Table 3).
Cross HI test
To determine the specificity of the HI test in identification of
subtype-specific antibodies, the HI test was performed with H1–H13
Figure 4. H5 peptide ELISA was performed with sera from chickens immunized with (a) H5N1 virus strains from different clades,
covering clade 1, 2.1, 2.1.1, 2.1.2, 2.1.3, 2.2, 2.3, 0, 7, 4 and8 (b) influenza A viruses H1–H13[H1(NH)- newhuman & (SF)- seasonalflu)]
andH16subtypes. Sera were adjustedto HI titerof 16to homologousvirusesanddiluted 1:100 prior touseforanalysis. Theresultswere expressedas
the mean of absorbance value (n=4/group, whiskers above bars represent the standard deviation of the mean). CS: pre-immune chicken serum.
doi:10.1371/journal.pone.0020737.g004
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antiserum with heterologous antigen was minimal and negligible
(#1:4). However,H5antiserum and H2 antigen exhibited high cross-
reactivity (1:16). The cross-reactivity between these two subtypes is
because of the relatively high HA sequence similarity [22].
Immunofluorescence assay
To determine the specificity of using H5 HA1 antigen in
identification of subtype-specific antibodies, indirect immuno-
fluorescence assay with sf-9 cells infected with recombinant
baculovirus expressing H5 HA1 was conducted against H1–H13
and H16 antisera. Antisera to different H5N1 viruses yielded
strong cytoplasmic immunoflurosence (Fig. 1 shows the
representative images, other data not shown). Cross-reactivity
was observed with antibodies of subtype H1, H2, H3, H6, H7
and H12 (Fig. 1). The positive signal from these non-H5
subtypes could be explained by the sequence homology with H5
and also .40% amino acid identity among influenza A subtypes
[23,24].
Immunodot blot
With the advantage of eliminating HA2 that presents in HI test,
we conducted immunodot blot assay using purified HA1 proteins
of subtype H1–H13 and H16 to determine the specificity of HA1
in the identification of subtype-specific antibodies (Fig. 2). The H5
antisera reacted strongly to H5 HA1 but cross reactivity was
observed with HA1 of H1, H2, H3, H6, H7 and H12 subtype
(Fig. 3).
Development of H5 peptide ELISA
The peptide of amino acids sequence ‘‘CNTQCNTPMGAINSS’’
incorporated in the H5 peptide ELISA comprises the highly
conserved and antigenic epitope (CNTQCNTP) of H5 HA as
published in our previous study [9]. The specificity and sensitivity of
the H5 peptide ELISA was examined using antisera from
experimentally immunized chickens. Chicken sera collected 10 days
after the 2nd immunization were adjusted to HI titer of 16 with the
homologous virus to normalize antibody concentration and further
diluted 1:100 prior to use in H5 peptide ELISA. Figure 4a shows the
absorbance values of H5N1 virus strains from different clades,
c o v e r i n gc l a d e0 ,1 ,2 . 1 ,2 . 1 . 1 ,2 . 1 . 2 ,2 . 1 . 3 ,2 . 2 ,2 . 3 ,4 ,7a n d8 .T h e
signal was considered to be positive when the absorbance was 3 times
higher than that of the control serum. Absorbance values of all H5N1
serum samples were significantly higher than control serum and at
least 5 times higher than that of the non-H5 subtypes viruses, with an
average absorbance of 1.6 (Fig. 4a). No cross-reactivity was observed
for any of the non-H5 subtype sera tested, and the average
absorbance readings was 0.089 (Fig. 4b). These results indicate that
the H5 peptide ELISA could positively identify serum samples
containing antibodies to H5 and tested negative for sera containing
antibodies to other HA subtypes.
Human serum samples
To determine whether the peptide ‘‘CNTQCNTPMGAINSS’’
in the H5 peptide ELISA could recognize antibodies elicited by
natural H5N1 infection in humans, convalescent serum samples
from patients with laboratory-confirmed H5N1 infection were
evaluated. A total of twelve out of fifteen serum samples obtained
from patients from Vietnam and Indonesia tested positive in H5
peptide ELISA, with absorbance values of at least 5 times higher
than the average absorbance value of normal human sera
(0.0739) (Table 4). Even though some of these human serum
samples showed a low HI titer of 4–16 only (Table 4), these serum
samples were tested positive in EB-ELISA with mAb 5F8,
indicating that the sensitivity of H5 peptide ELISA is comparable
to that of EB-ELISA (Table 4). In addition, serum neutralization
titer showed a comparative result to EB-ELISA and Peptide-
ELISA (Table 4). Three serum samples collected 2 days after the
onset of infection, when antibodies had not been produced were
tested negative in serum neutralization, EB-ELISA and peptide-
ELISA (Table 4). However, these samples showed an unspecific
Table 4. Analysis of human serum samples in H5 epitope-
ELISA.
Human
samples HI assay SN EB-ELISA?
Pep-ELISA
*Mean ± SD Pep-ELISA
H5N1 infected samples
Vietnam
31209 128 .1280 P 0.89960.007 P
31203 128 .1280 P 0.85860.006 P
30402 64 .640 P 0.71260.007 P
31244 4–8 80 P 0.47260.0071 P
30583 16 160 P 0.51360.0071 P
30768 16–32 320 P 0.62660.006 P
30777 16 320 P 0.53060.007 P
31D-11 16 320 P 0.65360.007 P
‘ELI 138 8 20 N 0.12160.006 N
‘30406 16 40 N 0.13260.007 N
‘CM1541 8 20 N 0.11960.006 N
Indonesia
292 32 640 P 0.65860.0051 P
554 32 .320 P 0.59860.006 P
645 16 160 P 0.55560.006 P
828 16 160 P 0.54960.007 P
Seasonal influenza infection samples
Singapore
9115 8 20 N 0.08560.006 N
9129 ,8 20 N 0.072360.007 N
9873 ,8 20 N 0.081060.008 N
9106 8 ,40 N 0.08960.007 N
9708 ,8 20 N 0.073560.006 N
9824 ,8 20 N 0.071260.006 N
9872 8 ,40 N 0.086760.006 N
9624 ,8 20 N 0.069860.007 N
9792 ,8 20 N 0.071460.007 N
9140 ,8 20 N 0.072460.007 N
9151 8 20 N 0.073160.007 N
9159 ,8 20 N 0.074360.005 N
9216 ,8 20 N 0.072260.007 N
9286 8 ,40 N 0.085460.007 N
9398 8 ,40 N 0.091060.006 N
Normal healthy controls
N=20 0.0 0.0 N 0.073960.04 N
?Inhibition above the cut-off value of $30% blocking was considered positive
(P).
*mean 6 standard deviation of duplicate values of 2 independent experiments.
‘Serum collected 2 days after the onset of infection.
P: positive, N: negative.
doi:10.1371/journal.pone.0020737.t004
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seasonal influenza A virus infection yielded negative results in H5
peptide ELISA, with a maximum absorbance of 0.091 (Table 4).
However, some of these sera showed a HI titer of 8 against H5N1
virus, indicating some degree of cross-reactivity (Table 4). These
data further demonstrate the reliability of H5 peptide ELISA in
the detection of H5 antibodies in serum samples and minimal
cross-reactivity due to antibodies elicited by seasonal influenza
viruses.
Discussion
Successful control of H5N1 HPAI viruses requires active
serological surveillance in animals and humans. Despite the
limitations of conventional methods such as HI and microneu-
tralization assay for serological surveillance, the main drawback of
these methods is their impracticality for field investigation. We
reported an EB-ELISA for detection of H5 antibodies based on a
mAb that recognizes a highly conserved and antigenic epitope
‘‘CNTKCQTP’’ in influenza H5 HA [9]. However, this format is
costly and less ideal to be developed into a rapid diagnostic kit.
Peptide ELISA has been used for sensitive and specific detection
of biomarker antibodies in the diagnosis of many diseases [6,25],
and antibodies to other viral pathogens [7,26]. To develop a
robust, simple and cost-effective diagnostic tool for rapid H5
antibody detection that is suitable for field use, we incorporated
the H5 HA specific epitope (CNTKCQTP) into peptide ELISA
format. Thorough characteristic of this epitope in all influenza A
viruses in our previous study showed that the conservation is 100%
in all human H5N1 viruses and near complete absence in other
subtypes [9]. In addition, the data from both our studies showed
that this epitope is highly antigenic as antibodies to this epitope
were readily detected in sera from chickens immunized with
divergent clades of H5N1 viruses. Furthermore, in agreement with
the characteristics of the epitope, the results showed that the H5
peptide ELISA based on the sequence of this epitope was 100%
specific in the detection of H5 antibodies.
Some degree of cross-reactivity was observed in HI assay, and
the immunodot blot and immunofluorescence assay that utilized
HA1 proteins as the antigens for the detection of H5 antibodies.
These observations are expected as number of studies have
reported invariable conserved region between different subtypes of
HA protein [3,22,27,28]. Therefore, it further indicates the
advantage and essential of the peptide approach to eliminate
homologous epitopes between subtypes in order to achieve near
absolute specificity.
The performance characteristic of the H5 peptide-ELISA was
evaluated with human serum specimens with confirmed H5N1
infection history. In agreement with results obtained from
experimental immunized chicken antisera, the H5 peptide-ELISA
detected H5N1 antibodies in convalescent human sera. In
addition, no false-positive test was observed with convalescent
sera from seasonal influenza virus infection. We reported the high
sensitivity of EB-ELISA [9], and the H5 peptide-ELISA in this
study demonstrated comparable sensitivity with that of EB-ELISA.
With the limited number of human serum samples from confirmed
H5N1 individuals in this study, the H5 peptide-ELISA exhibited
100% sensitivity (n=12) and 100% specificity (n=35).
In summary, the H5 peptide-ELISA developed in this study
provides sensitive and highly specific detection of H5 antibodies.
Although the serum neutralization is considered as the gold
standard for serodiagnosis, it has some drawbacks of time
consuming and the need of heightened containment and use of
live virus. The data suggests that this H5 peptide-ELISA based on
the highly conserved and antigenic H5 HA epitope
‘‘CNTKCQTPMGAINSS’’ could be formatted as a rapid field
test based on dipstick or lateral flow technologies, which greatly
facilitate field investigation. As suggested by the global strategy for
prevention and control of H5N1 HPAI, every country should have
a surveillance system for detecting the virus in poultry [29].
Effective control of HPAI in poultry is critical as it limits the
exposure of humans to the virus, thus diminishing the opportu-
nities of the development of novel virus that acquires the ability to
transmit from human to human [29]. Rapid diagnostic kits as such
are inexpensive and easy to perform which would be very
beneficial for rural areas and developing countries, where
expertise, infrastructure and resources are limited.
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